Pharmacogenomics An Introduction and Clinical Perspective

Joseph S. Bertino Jr., Pharm.D. is an Associate Professor of Clinical Pharmacology in Medicine at the College of Physicians and Surgeons, Columbia University, New York, NY. His research interests are varied and include work with vaccines, antimicrobial pharmacokinetics and pharmacodynamics, treatment of hypertension, pharmacogenetics and pharmacogenomics. Dr. Bertino received the Pharm.D. degree from SUNY at Buffalo. He has published over 100 original research papers, review articles and book chapters. His publications have included work in the area of antimicrobial pharmacokinetics, pharmacodynamics and toxicity, drug-drug interactions, general clinical pharmacology, vaccine pharmacology and the application of pharmacogenetics to the drug development process. Joseph D. Ma, PharmD is an Assistant Professor at the University of California San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences. He received his Pharmacy Doctorate from the University of California, San Francisco. He then completed a 2-year fellowship in clinical pharmacology at Bassett Healthcare, Cooperstown, NY. Upon fellowship completion, Dr. Ma was employed at Amgen, Inc. and was responsible for phase I protocol development and study operational and managerial functions. Dr. Ma joined UCSD in 2007. He serves as co-coordinator for the winter quarter Therapeutics course and for a spring quarter elective titled Drug Discovery, Development, and Commercialization. His research interests are in examining pharmacokinetic and pharmacodynamic variability and in the optimization of drugs as probes to phenotype drug-metabolizing enzyme activity. Angela Kashuba, PharmD is an Associate Professor of Pharmacy at the University of North Carolina in Chappel Hill. Ms. Kashuba received two grants specifically on pharmcgenomics on the elderly. C. Lindsay DeVane, Pharm.D. is Professor of Psychiatry and Behavioral Sciences and Vice Chair for Research in the Department of Psychiatry at the Medical University of South Carolina (MUSC) in Charleston, SC. He directs the Laboratory of Drug Disposition and Pharmacogenetics in the Darby Children’s Research Institute and oversees operation of the core laboratories of MUSC’s General Clinical Research Center. Professor Uwe Fuhr MD, is Clinical Pharmacologist at University of Cologne, Cologne, Germany, Faculty of Medicine. He is a native of Saarbruecken, Germany, and attended Johann Wolfgang Goethe University in Frankfurt am Main, Germany, as an undergraduate in Medicine where he obtained state registration as a physician in 1987.

Section I. General Concepts
1. Developing Perspectives on Pharmacogenomics
2. Genetic Concepts of Pharmacogenomics: Basic Review of DNA, Genes, Polymorphisms, Haplotypes and Nomenclature
3. Analytical Methods to Identify Genetic Variations and Bioinformatics
4. Regulatory Considerations in Pharmacogenomics at EMA and US FDA
5. Ethical, Legal, and Social Issues Associated with Pharmacogenomics
6A. Pharmacogenetics of Cytochrome P450
6B. Phase II Drug-Metabolizing Enzymes
7. Drug Transporters
8. Nongenetic Influences on Drug Metabolism
9. Public Access to Pharmacogenomic Testing and Patient Counseling
10. Understanding the Use of Pharmacoeconomic Analysis to Assess the Economic Impact of Pharmacogenomic Testing

Section II. Clinical Application of Pharmacogenomics
11. Cardiovascular Pharmacogenomics
12. Pharmacogenomics and Pharmacogenetics for Infectious Diseases
13. Pharmacogenomics in Oncology
14. Psychiatry and Addiction Medicine
15. Immunology,Transplantation,and Vaccines
16. Pharmacogenomics in Neurology
17A. Pharmacogenomics of Gastrointestinal Drugs: Focus on Proton Pump Inhibitors
17B. Genomics and the Kidney

Index